Zegfrovy is a significant breakthrough in precision oncology for patients with non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertion mutations. It sets a new benchmark for patients with few therapy alternatives by combining clinically significant efficacy, oral convenience, and highly selective EGFR inhibition. Its quick approval highlights the critical need for efficient treatments in this patient group, and further research attempts to increase its therapeutic benefit in first-line and combo treatment settings.